Flavonoid Scaffold Redesigned via Bioisosteric Replacement to Target Aromatase in ER+ Breast Cancer
- Aromatase (CYP19A1) catalyzes the final step converting androgens to estrogens, and its activity drives tumor proliferation in estrogen receptor-positive (ER+) breast cancer, making it a long-validated target for hormonal therapy.
- Existing steroidal and nonsteroidal aromatase inhibitors (AIs) are effective as first-line treatments but face limitations from acquired resistance and off-target/tolerability issues, motivating a search for new chemical starting points.
- Researchers applied bioisosteric replacement strategies to a flavonoid-derived scaffold, a plant-derived chemotype structurally distinct from current AI drug classes, to generate a series of novel candidate inhibitors.
- The substitutions were assessed computationally for how they might alter predicted binding within the CYP19A1 active site, alongside their effects on physicochemical and ADME-relevant properties.
- The overall goal is a lead series that suppresses estradiol biosynthesis while addressing some of the structural liabilities associated with existing AI chemotypes.
A flavonoid core is a bold starting point — it's structurally miles from the triazole-based nonsteroidal AIs (letrozole, anastrozole) and steroidal exemestane, but that novelty cuts both ways. First question: what's actually coordinating the heme iron? Nonsteroidal AIs work because that triazole/imidazole nitrogen chelates Fe3+ — if the bioisosteric swaps didn't install an equivalent, the "improved binding" predictions may be modeling the wrong interaction entirely. Second, flavonoids are notorious for glucuronidation, poor solubility, and promiscuous CYP inhibition (isoform selectivity is the whole AI liability story, not just CYP19A1 potency) — bioisosteric replacement can just relocate those ADME problems rather than fix them. And this is docking/property prediction only; no IC50s, no CYP19A1/CYP3A4 selectivity ratios, no cell data. Promising scaffold idea, but until there's a measured Ki, I'm filing this under "watch, don't chase."